Forum Agenda

July 24,09:00-12:10

Innovative Small Molecule Chemical Drugs Session

Stay tuned

09:00-09:20   Data-Driven Insights into Global Trends in Small Molecule Drug Discovery
Li Tianquan:Founder & Vice President ofYaozhi.com

 

09:20-09:35   Emerging Trends in Small Molecule Drug Discovery: From Target Selection to Pipeline Strategy
Wang Kuifeng:Founder & CEO, GenHouse Bio


09:35-09:50   Haisco's Innovation Strategy for Novel Drug Discovery
Yan Pangke:General Manager, Haisco Pharmaceutical Group


09:50-10:05   Structural Biology Enabling Proximity-Based Drug Discovery
Jiaquan  Wu:Biortus SVP


10:05-10:20   Automation Strategies in Drug Discovery
JI NIE:Senior Product Manager, Beckman Coulter Life Sciences


10:20-10:35   Not All JAKi’s are Created Equal
Wan Zhaokui:Chairman of Board & CEO, Lynk Pharmaceuticals


10:35-10:50   Trends in the application of Spray Drying for Small Molecule Drug Development
David Brugat Plata:Production Manager,ESTEVE


10:50-11:05   TSN1611: Tyligand's Selective KRAS G12D Inhibitor
Tony  Zhang:Founder & CEO, Tyligand Bioscience


11:05-11:20   Mechanism-Driven Innovation: Fourth-Generation BTK Inhibitor Lorbretinib for Overcoming B-Cell Lymphoma Resistance
Yi   Chen:Co-founder, Lupeng Pharmaceuticals


11:20-11:35   From Single Targets to Multi-System Modulation: Salubris' Strategy for CKM Syndrome Drug Development
Mu Shengmei:CMO, Salubris Pharmaceuticals


11:35-11:50   Innovative Drug Development for Chronic Hepatitis B
George Zhang:Chairman, Akeylink Biotechnology


11:50-12:10   FIC/BIC Drug Discovery Based on Validated Targets
Deng Haibing:head of medicinal chemistry, Abbisko